Mercado v. Bayer Healthcare Pharmaceuticals Inc.
Filing
38
MEMORANDUM Opinion and Order. The Court grants in part and denies in part defendant's motion to dismiss 21 . Counts I, II and IV-VI are dismissed without prejudice. Count VII survives to the extent that it is based on misrepresentations made by defendant on Mirena's labeling or packaging, but is otherwise dismissed without prejudice. Signed by the Honorable Jorge L. Alonso on 6/5/2015:Notice mailed by judge's staff (ntf, )
IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION
IVETTE MERCADO,
Plaintiff,
v.
BAYER HEALTHCARE
PHARMACEUTICALS INC.,
Defendants.
)
)
)
)
)
)
)
)
)
)
No. 14 C 6699
Judge Jorge L. Alonso
MEMORANDUM OPINION AND ORDER
Plaintiff Ivette Mercado suffered an infection after her physician inserted a Mirena
intrauterine device, a contraceptive device manufactured and sold by defendant Bayer Healthcare
Pharmaceuticals Inc. (“Bayer”). Plaintiff filed this products liability action against defendant,
asserting claims of strict products liability, negligence, breach of express and implied warranty
and misrepresentation. Defendant has moved to dismiss six of the complaint’s seven counts for
failing to state a claim under Rule 12(b)(6).
For the reasons set forth below, the motion is
granted in part and denied in part.
I.
BACKGROUND
Mirena is a T-shaped polyethylene frame with a steroid reservoir that releases
levonorgestrel, a prescription medication used as a contraceptive. (Am. Compl. ¶ 6.) In the fall
of 2013, plaintiff’s physician inserted a Mirena into plaintiff. (Id. ¶ 15.) Just a couple of weeks
later, plaintiff returned to her physician complaining of lower abdominal pain, and the physician
prescribed antibiotics for suspected pelvic inflammatory disease. (Id. ¶ 17.) Plaintiff’s condition
did not improve, and on December 3, 2013, plaintiff was admitted to the intensive care unit at
Advocate Lutheran General Hospital. (Id. ¶ 18.) She developed toxic shock syndrome due to
Group A Streptococcus (id.), and her Mirena was removed on December 7, 2013. (Id. ¶¶ 18-19.)
Plaintiff alleges that the Mirena label does not warn about the possibility of developing
toxic shock syndrome (id. ¶ 8) or other risks (id. ¶¶ 11-12), defendant failed to alter the product
packaging in response to reports of abdominal pain and pelvic pain in women who had had
Mirenas inserted (id. ¶ 9), and defendant failed to warn of the risks associated with Mirena (id. at
¶¶ 20-21).
Plaintiff’s complaint contains seven counts: strict liability defective manufacturing
(Count I), design defect (Count II), failure to warn, (Count III), negligence (Count IV), breach of
express warranty (Count V) 1, breach of implied warranty (Count VI), and misrepresentation and
concealment (Count VII). Defendant has moved to dismiss all but Count III, the failure to warn
count.
II.
LEGAL STANDARDS
“A motion under Rule 12(b)(6) tests whether the complaint states a claim on which relief
may be granted.” Richards v. Mitcheff, 696 F.3d 635, 637 (7th Cir. 2012). Under Rule 8(a)(2), a
complaint must include “a short and plain statement of the claim showing that the pleader is
entitled to relief.” Fed. R. Civ. P. 8(a)(2). The short and plain statement under Rule 8(a)(2) must
“give the defendant fair notice of what the claim is and the grounds upon which it rests.” Bell
Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (ellipsis omitted).
Under federal notice-pleading standards, a plaintiff’s “[f]actual allegations must be
enough to raise a right to relief above the speculative level.” Id. Stated differently, “a complaint
must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible
1
Plaintiff has numbered both her breach of express warranty count and her breach of implied warranty count as
“Count VI.” Where it is necessary to refer to the counts by number, the Court will refer to the express warranty
count as “Count V” because it is the fifth count in sequence.
2
on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Twombly, 550 U.S. at 570).
“A claim has facial plausibility when the plaintiff pleads factual content that allows the court to
draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. (citing
Twombly, 550 U.S. at 556). “In reviewing the sufficiency of a complaint under the plausibility
standard, [courts must] accept the well-pleaded facts in the complaint as true, but [they] ‘need[ ]
not accept as true legal conclusions, or threadbare recitals of the elements of a cause of action,
supported by mere conclusory statements.’” Alam v. Miller Brewing Co., 709 F.3d 662, 665–66
(7th Cir. 2013) (quoting Brooks v. Ross, 578 F.3d 574, 581 (7th Cir. 2009)).
III.
DEFECTIVE MANUFACTURING, DESIGN DEFECT, NEGLIGENCE, BREACH
OF IMPLIED WARRANTY
Defendant contends that plaintiff’s claims of strict liability defective manufacturing
(Count I) and design defect (Count II), negligence (Count IV), and breach of implied warranty
(Count VI) must be dismissed because they are merely formulaic recitations of elements,
unadorned by specific facts. The Court agrees.
These claims require plaintiff to allege, among other elements, that there was an
unreasonably dangerous defect in the product (Counts I and II); defendant proximately caused
plaintiff’s injury by breaching a duty (Count IV); or the product was not of merchantable quality
and not fit for the ordinary purposes for which the product is used (Count IV). Plaintiff never so
much as hints at what the defect was in the Mirena that caused plaintiff’s infection and related
injuries. This deficiency is fatal to these claims.
Without any factual allegations at all relating to a particular condition, quality or attribute
of the product that caused the injury, the Court cannot infer “more than the mere possibility of
misconduct.” Iqbal, 556 U.S. at 679. It appears to be as likely that the infection was due to
negligence on the part of the inserting physician or the staff of the facility where the Mirena was
3
inserted as it is that the infection was due to any negligence on the part of defendant or due to
some condition or quality of the product that makes the defendant liable in strict liability or for
breach of the implied warranty of merchantability. Based on these sparse factual allegations,
plaintiff’s injury is “just as much in line” with alternative explanations that have nothing to do
with defendant as with her claim that her injury was caused by the Mirena, see Brooks v. Ross,
578 F.3d 574, 581-82 (7th Cir. 2009) (citing Twombly, 550 U.S. at 554). In pleading Counts I,
II, IV and VI, plaintiff has not raised her “right to relief above the speculative level.” Twombly,
550 U.S. at 555. These counts are dismissed.
IV.
MISREPRESENTATION (COUNT VII)
Plaintiff also alleges that defendant had knowledge of certain risks posed by use of
Mirena, including the risk of pelvic pain and inflammation; that defendant concealed safety
issues with Mirena to induce physicians and patients to use it; and that “Plaintiff and Plaintiff’s
healthcare providers relied upon Defendant’s representations to them that Mirena was safe for
human use and that the Defendant’s labeling, advertising, and promotions fully described all
known risks of Mirena,” (Am. Compl. ¶ 87). Defendant claims that these allegations do not
specify the time, content, and place of any alleged misrepresentations, and therefore do not meet
the requirements of Rule 9.
The Court agrees with defendant that Count VII is not clearly or precisely drafted and
plaintiff seems at times to base her misrepresentation claim at least partially on unspecified
misrepresentations, in violation of Rule 9.
However, in her response brief, plaintiff states that
“these alleged misrepresentations were placed on the labels and packaging of the product.”
(Resp. at 10.) To the extent that plaintiff is clarifying that the “misrepresentations” she is
referring to were made within the labeling and packaging of the product, the Court concludes
that the allegations of Count VII are made with sufficient particularity to survive a motion to
4
dismiss. To the extent that the “misrepresentations” she refers to in her complaint are made
somewhere other than in the labeling, packaging and package inserts, Count VII is dismissed
with leave to amend so that plaintiff can provide the “who, what, where, when and how” of the
alleged misrepresentations. See Bank of Am., N.A., v. Knight, 725 F.3d 815, 818 (7th Cir. 2013).
V.
BREACH OF EXPRESS WARRANTY (COUNT V)
Defendant claims that plaintiff’s express warranty claim must be dismissed both because
plaintiff has no contractual privity with defendant and because plaintiff does not allege with any
specificity what “affirmation, promise, description or sample formed part of the basis of the
bargain,” much less what the exact terms of the express warranty were. (Mem. Supp. Mot.
Dismiss at 9-10 (citing Heisner ex rel. Heisner v. Genzyme Corp., No. 08-C-593, 2008 WL
2940811, at *8-9 (N.D. Ill. July 25, 2008)).
The Court is inclined to agree, and plaintiff makes no argument to the contrary; her
response brief omits any mention of her express warranty claim. Because plaintiff apparently
concedes that she has failed to state a claim for breach of an express warranty, Count V is
dismissed.
5
CONCLUSION
For the reasons set forth above, the Court grants in part and denies in part defendant’s
motion to dismiss [21]. Counts I, II and IV-VI are dismissed without prejudice. Count VII
survives to the extent that it is based on misrepresentations made by defendant on Mirena’s
labeling or packaging, but is otherwise dismissed without prejudice.
SO ORDERED.
ENTERED: June 5, 2015
______________________
HON. JORGE L. ALONSO
United States District Judge
6
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?